why doesn't glp-1 work for me GLP-1: Genetic Variants Related to RA Medications Why Your GLP-1 Isn't Working

The LEAD-3 study found that liraglutide monotherapy reduced glycosylated hemoglobin (A1C), body weight, and blood pressure compared to glimepiride (36)

Table 1: Initial use restrictions for Wegovy by commercial plans Source: Clarivate Fingertip Restrictions and payers respective prior authorization documents In addition to a relatively light hand in restricting access, Aetna, Cigna, and Anthem list Wegovy on Tier 2 of their commercial and employer formularies, reflecting widespread coverage for the drug (Fingertip Analytics, accessed February 2024)

doi: 10.1016/j.neuropharm.2021.108662 106 AlvarezEMartinezMDRonceroIChowenJAGarcia-CuarteroBGispertJDet al

SGLT2i + DPP4i FDCs: Clinical Evidence Overview Three SGLT2i + DPP4i FDCs are currently by the US Food and Drug Administration (USFDA), but only two of these are approved for use and commercially available in India